Кларитромицин: фармакологические особенности и терапевтические возможности

1. Schlunzen F, Zarivach R, Harms J et al. Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature 2001; 413: 814–21.
2. Poehlsgaard J, Douthwaite S. Macrolide antibiotic interaction and resistance on the bacterial ribosome. Curr Opin Investigat Drugs 2003; 4: 140–8.
3. Lai CJ, Weisblum B. Altered methylation of ribosomal RNA in an erythromycin-resistant strain of Staphylococcus aureus. Proceedings of the National Academy of Sciences of the United States of America 1971; 68: 856–60.
4. Weisblum B. Erythromycin resistance by ribosome modification. Antimicrob Agents Chemother 1995; 39: 577–85.
5. Leclercq R, Courvalin P. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob Agents Chemother 1991; 35: 1267–72.
6. Tait-Kamradt A, Davies T, Appelbaum PC et al. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother 2000; 44: 3395–401.
7. Peric M, Bozdogan B, Jacobs MR, Appelbaum PC. Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates. Antimicrob Agents Chemother 2003; 47: 1017–22.
8. Clancy J, Petitpas J, Dib-Hajj F et al. Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA, from Streptococcus pyogenes. Molecular Microbiology 1996; 22: 867–79.
9. Hardy DJ, Hensey DM, Beyer JM et al. Comparative in vitro activities of new 14-, 15- and 16-membered macrolides. Antimicrob Agents Chemother 1988; 32: 1710–9.
10. Bahal N, Nahata MC. The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. Ann Pharm 1992; 26: 46–55.
11. Sturgill MG, Rapp RP. Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles. Ann Pharm 1992; 26: 1099–108.
12. Kim SH, Song J-H, Chung DR et al. Changing Trends in Antimicrobial Resistance and Serotypes of Streptococcus pneumoniae Isolates in Asian Countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study. Antimicrob Agents Chemother 2012; 56: 1418–26.
13. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2010. Ann Rep Eur Antimicrob Resistance Surveillance Network (EARS-Net). Stockholm: ECDC, 2011.
14. Сидоренко С.В., Грудинина С.А., Филимонова О.Ю. и др. Резистентность к макролидам и линкозамидам среди Streptococcus pneumoniae и Streptococcus pyogenes в Российской Федерации. Клин. фармакол. тер. 2008; 17: 1–5.
15. Reinert RR, Filimonova OY, Al-Lahham A et al. Mechanisms of macrolide resistance among Streptococcus pneumoniae isolates from Russia. Antimicrob Agents Chemother 2008; 52: 2260–2.
16. Козлов Р.С., Сивая О.В., Кречикова О.И., Иванчик Н.В. Динамика резистентности Streptococcus pneumoniae к антибиотикам в России за период 1999–2009 гг. (Результаты многоцентрового проспективного исследования ПеГАС). Клин. микробиол. антимикроб. химиотер. 2010; 12: 1–13.
17. Amsden GW. Anti-inflammatory effects of macrolides – an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005; 55: 10–21.
18. Hoyt JC, Robbins RA. Macrolide antibiotics and pulmonary inflammation. FEMS microbiology letters 2001; 205: 1–7.
19. Culic O, Erakovic V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001; 429: 209–29.
20. Bosnar M, Bosnjak B, Cuzic S et al. Azithromycin and clarithromycin inhibit lipopolysaccharide-induced murine pulmonary neutrophilia mainly through effects on macrophage-derived granulocyte-macrophage colony-stimulating factor and interleukin-1beta. J Pharmacol Exp Ther 2009; 331: 104–13.
21. Desaki M, Takizawa H, Ohtoshi T et al. Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Communications 2000; 267: 124–8.
22. Shinkai M, Foster GH, Rubin BK. Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells. Am J Physiology Lung Cell Mol Physiology 2006; 290: L75–85.
23. Shinkai M, Lopez-Boado YS, Rubin BK. Clarithromycin has an immunomodulatory effect on ERK-mediated inflammation induced by Pseudomonas aeruginosa flagellin. J Antimicrob Chemother 2007; 59: 1096–101.
24. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microb Rev 2010; 23: 590–615.
25. Tateda K, Standiford TJ, Pechere JC, Yamaguchi K. Regulatory effects of macrolides on bacterial virulence: potential role as quorum-sensing inhibitors. Curr Pharm Des 2004; 10: 3055–65.
26. Chu S, Wilson DS, Deaton RL et al. Single- and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial. J Clin Pharmacol 1993; 33: 719–26.
27. Chu SY, Wilson DS, Guay DR, Craft C: Clarithromycin pharmacokinetics in healthy young and elderly volunteers. J Clin Pharmacol 1992; 32: 1045–9.
28. Rodvold KA. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokin 1999; 37: 385–98.
29. Rodvold KA, George JM, Yoo L. Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents. Clin Pharmacokin 2011; 50: 637–64.
30. Periti P, Mazzei T. Clarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosage regimen. 
J Chemotherapy 1999; 11: 11–27.
31. Mandell LA, Wunderink RG, Anzueto A et al: Infectious Diseases Society of America. American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl. 2): S27–72.
32. Woodhead M, Blasi F, Ewig S et al. Guidelines for the management of adult lower respiratory tract infections-full version. Clin Microb Infection 2011; 17 (Suppl. 6): E1–59.
33. Lim WS, Baudouin SV, George RC et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64 (Suppl. 3): iii1–55.
34. Внебольничная пневмония у взрослых: Практические рекомендации по диагностике, лечению и профилактике. Пособие для врачей. Российское респираторное общество. МАКМАХ. М., 2010.
35. Gotfried MH, Dattani D, Riffer E et al. A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. Clin Therapeutics 2002; 24: 736–51.

С.В.Сидоренко 

Научно-исследовательский институт детских инфекций, Санкт-Петербург